A Randomised Controlled Trial Comparing Intraoperative To Conventional Radiotherapy In Women With Early Beast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$874,046.00
Summary
With the advent of breast screening in Australia many women are diagnosed with small low risk cancers that can be treated with breast conserving therapy with good outcomes. Surgery and radiotherapy in this situation are used to minimise the risk of local recurrence. It is now being questioned whether we can tailor radiotherapy to suit individual patients rather than recommending the daily 6-7 weeks of standard external beam radiotherapy to all patients. This trial aims to answer this question as ....With the advent of breast screening in Australia many women are diagnosed with small low risk cancers that can be treated with breast conserving therapy with good outcomes. Surgery and radiotherapy in this situation are used to minimise the risk of local recurrence. It is now being questioned whether we can tailor radiotherapy to suit individual patients rather than recommending the daily 6-7 weeks of standard external beam radiotherapy to all patients. This trial aims to answer this question as a new device which can deliver radiotherapy intraoperatively in a single session has now been tested and proven safe to use in the breast. The main objective of this trial is to demonstrate that a single dose of radiotherapy delivered intraoperatively (IORT) gives an equivalent local control rate to standard external beam radiotherapy in women with early low risk breast cancer who are suitable for breast conserving therapy. Other objectives include comparing the two treatments with respect to; disease-free-overall survival, cosmetic outcome, patient satisfaction-preference, quality of life and cost benefit. If the study finds that IORT alone after breast conserving surgery is as effective in achieving local control as standard external beam radiotherapy, a major benefit to patients would be shorter treatment duration by avoiding the 6-7 weeks of standard radiotherapy. A reduction in the number of early breast cancer patients requiring access to standard radiotherapy would also benefit treatment centres and other cancer patients by reducing the waiting times for radiotherapy. Consumer groups have supported the concept from the beginning and there has been recent increase in level of support by originally unsupportive groups. Of great significance is this trial offers an opportunity to formally investigate the efficacy of delivering IORT in the safe confines of a clinical trial, before allowing it to become a standard treatment which is occurring in other countries.Read moreRead less
The TOPGEAR Trial; Trial Of Preoperative Therapy For Gastric And Esophagogastric Junction Adenocarcinoma
Funder
National Health and Medical Research Council
Funding Amount
$1,974,558.00
Summary
While surgery to remove gastric (stomach) cancer has been traditionally accepted as the only way to potentially cure the disease, there have been several recent advances using chemotherapy and/or radiotherapy both before and after surgery. However doctors' opinions remain divided regarding the best treatments to give and in what order. This randomised clinical trial will address the important question of whether combined chemotherapy plus radiotherapy is more effective than chemotherapy alone in ....While surgery to remove gastric (stomach) cancer has been traditionally accepted as the only way to potentially cure the disease, there have been several recent advances using chemotherapy and/or radiotherapy both before and after surgery. However doctors' opinions remain divided regarding the best treatments to give and in what order. This randomised clinical trial will address the important question of whether combined chemotherapy plus radiotherapy is more effective than chemotherapy alone in improving cure rates for stomach cancer.Read moreRead less
A Randomised Trial Of Surgery Versus Surgery Plus Radiotherapy For Regional Control In Patients With Stage 3 Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$305,163.00
Summary
Melanoma is a common disease in Australia. When it has spread to lymph glands it has a poor prognosis. If not controlled it can lead to severe local symptoms including pain, bleeding and disabilty. This is a world first clinical trial involving radiotherapy given after surgery for melanoma involving regional lymph glands. It involves a head to head comparison of surgery alone versus surgery followed by radiotherapy. The target is 230 patients, more than 160 being so far recruited. The main outco ....Melanoma is a common disease in Australia. When it has spread to lymph glands it has a poor prognosis. If not controlled it can lead to severe local symptoms including pain, bleeding and disabilty. This is a world first clinical trial involving radiotherapy given after surgery for melanoma involving regional lymph glands. It involves a head to head comparison of surgery alone versus surgery followed by radiotherapy. The target is 230 patients, more than 160 being so far recruited. The main outcome of the study is control of melanoma in the lymph gland basin. Other outcomes are survival, time to recurrence, side-effects (such as lymphoedema) and quality of life. The trial currently involves 13 centres in Australia, New Zealand and the Netherlands. It is expects to be completed in 2007.Read moreRead less